Semaglutide vs VK2735: Approved GLP-1 Giant vs Emerging Dual Agonist

Introduction#

Semaglutide and VK2735 represent two generations of incretin-based obesity therapy. Semaglutide (Ozempic, Wegovy, Rybelsus) is the most prescribed GLP-1 receptor agonist worldwide, with proven efficacy across diabetes, obesity, and cardiovascular outcomes. VK2735 is Viking Therapeutics' dual GLP-1/GIP receptor agonist that has generated significant attention based on rapid weight loss observed in phase 2 trials.

The comparison is inherently asymmetric: semaglutide is a mature, FDA-approved therapy with an extensive evidence base, while VK2735 is an investigational agent with promising but limited data. Nonetheless, VK2735's early results -- particularly the rapid onset of weight loss and competitive oral formulation data -- suggest it could become a meaningful addition to the metabolic drug landscape if phase 3 trials confirm the phase 2 findings.

Mechanism of Action Comparison#

Semaglutide#

Semaglutide is a selective GLP-1 receptor agonist, a synthetic analog of human GLP-1(7-37) with an alpha-aminoisobutyric acid (Aib) substitution at position 8 for DPP-4 resistance and a C18 fatty diacid chain at lysine-26 for albumin binding. This extends the half-life to approximately 7 days, enabling once-weekly injection.

GLP-1 receptor activation produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction through hypothalamic and brainstem signaling. The glucose-dependent nature of insulin secretion minimizes hypoglycemia risk.

VK2735#

VK2735 is a dual GLP-1 and GIP receptor agonist, activating both incretin pathways simultaneously. This dual mechanism is conceptually similar to tirzepatide (Mounjaro/Zepbound), though VK2735 has a distinct molecular structure. GIP receptor co-activation is believed to potentiate insulin secretion, improve lipid metabolism, and enhance central appetite regulation through mechanisms complementary to GLP-1R signaling.

VK2735 is being developed in both subcutaneous injectable and oral tablet formulations, with the oral form showing competitive weight loss in phase 2 trials.

Mechanistic Comparison#

Dosing Comparison#

Semaglutide Dosing#

Semaglutide is available in three approved formulations:

• Ozempic (T2D): 0.25 mg weekly escalating to 0.5, 1, or 2 mg
• Wegovy (obesity): 0.25 mg weekly escalating over 16 weeks to 2.4 mg
• Rybelsus (oral): 3 mg daily escalating to 7 or 14 mg; must be taken on empty stomach with no more than 4 oz water, 30 minutes before food

VK2735 Dosing#

VK2735 dosing is investigational and has only been studied in phase 2:

• Subcutaneous (VENTURE): Multiple dose cohorts studied over 13 weeks with weekly injections; highest doses produced up to 14.7% weight loss
• Oral (VENTURE-Oral): Multiple dose cohorts including 90 mg studied over 13 weeks; highest doses produced up to 12.2% weight loss
• Maintenance strategy: An exploratory cohort demonstrated effective weight maintenance with down-titration from 90 mg to 30 mg orally

Final dose selection for phase 3 has not been publicly announced.

Side Effects Comparison#

Semaglutide Side Effects#

Semaglutide's GI adverse event profile is well characterized through programs involving over 25,000 participants plus 7+ years of post-marketing surveillance. Nausea occurs in 15-44%, vomiting in 5-24%, diarrhea in 8-30%, and constipation in 5-24%. Rates are higher at the 2.4 mg weight management dose. Most GI effects are mild to moderate, occur during escalation, and diminish with continued use.

Additional known effects include cholelithiasis (related to rapid weight loss), a modest heart rate increase of 2-4 bpm, and a boxed warning for thyroid C-cell tumors based on rodent data.

VK2735 Side Effects#

VK2735's safety data is limited to short-term phase 2 trials. In the VENTURE-Oral trial, vomiting was reported in 26% of VK2735-treated subjects compared with 10% placebo. However, 99% of GI-specific adverse events were classified as mild or moderate. The most common reasons for treatment discontinuation were GI-related.

Long-term safety, rare adverse events, and cardiovascular effects have not been characterized.

Safety Comparison Table#

Research Evidence Comparison#

Semaglutide Research#

Semaglutide has one of the most extensive evidence bases in metabolic medicine:

• SUSTAIN (T2D): Seven trials, >4,000 patients, HbA1c reductions of 1.2-2.2%
• PIONEER (oral T2D): Nine trials, >9,000 patients
• STEP (obesity): STEP 1 showed 14.9% mean weight loss at 68 weeks; STEP 5 confirmed 15.2% at 2 years
• SELECT (CV outcomes): 17,604 patients, 20% MACE reduction -- first anti-obesity drug with proven CV benefit

Evidence level: Very high -- large RCTs, cardiovascular outcomes, multiple formulations, long-term follow-up.

VK2735 Research#

VK2735's evidence base consists of phase 2 trials:

• VENTURE (subcutaneous): 176 adults with obesity, 13 weeks, up to 14.7% weight loss from baseline (placebo-adjusted 13.1%)
• VENTURE-Oral: Oral tablet formulation, 13 weeks, up to 12.2% weight loss vs 1.3% placebo
• Phase 3 VANQUISH program: Planned but not yet initiated at time of writing

Evidence level: Low -- promising phase 2 data only, short duration, small sample sizes, no head-to-head comparisons.

Key Differences Summary#

• Regulatory status: Semaglutide is FDA-approved with three commercial brands. VK2735 is investigational with phase 3 trials planned.
• Evidence base: Semaglutide has data from >25,000 trial participants and 7+ years of real-world use. VK2735 has phase 2 data from hundreds of patients over 13 weeks.
• Mechanism: Semaglutide targets GLP-1R only. VK2735 targets both GLP-1R and GIPR, potentially offering enhanced efficacy through dual incretin activation.
• Weight loss trajectory: VK2735 showed rapid weight loss in short 13-week trials (up to 14.7% SC, 12.2% oral) with weight still declining, suggesting potentially competitive long-term results. Semaglutide's 14.9% loss in STEP 1 was measured at 68 weeks.
• Cardiovascular data: Semaglutide has proven CV benefit from SELECT. VK2735 has no cardiovascular outcomes data.
• Oral formulation: Both have oral formulations, but semaglutide's (Rybelsus) requires strict fasting conditions while VK2735's oral version may have fewer restrictions (though final labeling is unknown).
• Availability: Semaglutide is widely available. VK2735 is years from potential market availability.

Conclusion#

This comparison reflects the difference between a proven, established therapy and a promising investigational agent. Semaglutide remains the standard of care with unmatched breadth of evidence including cardiovascular outcomes, long-term safety data, and multiple approved formulations. For any patient requiring treatment today, semaglutide is the evidence-based choice.

VK2735 represents a potentially compelling future option. Its dual GLP-1/GIP mechanism, rapid weight loss trajectory in short-term trials, and development in both injectable and oral formulations position it as a potential competitor to established therapies. The key question is whether phase 3 VANQUISH trials will confirm the efficacy and safety profile suggested by the phase 2 data, and whether VK2735 can differentiate itself in an increasingly competitive market that already includes the dual agonist tirzepatide.

Until VK2735 completes phase 3 development and achieves regulatory approval, semaglutide remains the clear recommendation for clinical use. Patients interested in VK2735 should discuss clinical trial participation with their healthcare provider.

Further Reading#

• Semaglutide Overview and Research Guide
• Semaglutide Side Effects
• Semaglutide Dosing Protocols
• VK2735 Overview and Research Guide
• VK2735 Side Effects
• VK2735 Dosing Protocols